Vontobel Holding’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Vontobel Holding’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,750	Closed	-$324K	–	1113
2023 Q3	$324K	Hold	6,750	–	–	﹤0.01%	880
2023 Q2	$351K	Hold	6,750	–	–	﹤0.01%	889
2023 Q1	$366K	Buy	6,750 +1,000	+17%	+$56.4K	﹤0.01%	846
2022 Q4	$332K	Buy	+5,750	New	+$324K	﹤0.01%	868
2022 Q2	–	Sell	-3,321	Closed	-$206K	–	1026
2022 Q1	$206K	Buy	3,321 +344	+12%	+$21.1K	﹤0.01%	997
2021 Q4	$241K	Buy	2,977 +266	+10%	+$22.8K	﹤0.01%	965
2021 Q3	$257K	Sell	2,711 -2,729	-50%	-$276K	﹤0.01%	977
2021 Q2	$536K	Buy	5,440 +4,425	+436%	+$386K	﹤0.01%	738
2021 Q1	$85K	Buy	+1,015	New	+$95.8K	﹤0.01%	955

Other funds holding BIB

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

CCWM

Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

CCP

Clarity Capital Partners Newport Beach, California $280M AUM 25.04% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vontobel Holding's BIB Position: Q4 2023 in Review

Vontobel Holding sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2023, closing a stake of 6,750 shares — an estimated $324K sold.

Vontobel Holding first reported a position in BIB in Q1 2021 and held it in 9 quarters. The position peaked at $536K in Q2 2021. 22 funds tracked by Wall St. Rank hold BIB as of Q4 2023.

Vontobel Holding reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2023 after selling out during the quarter.
Vontobel Holding sold 6,750 ProShares Ultra NASDAQ Biotechnology shares in Q4 2023, an estimated $324K.
Vontobel Holding first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2021 and held it in 9 quarters.
Vontobel Holding's ProShares Ultra NASDAQ Biotechnology position peaked at $536K in Q2 2021.
22 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2023.

Based on Vontobel Holding's 13F filing for Q4 2023, filed 30 Jan 2024.